AKIP Activators
AKIP, or A-Kinase Interacting Protein, refers to a group of proteins that interact with A-kinase, also known as Protein Kinase A (PKA). PKA is a critical enzyme in cellular signaling pathways, particularly in the response to cyclic AMP (cAMP). AKIP proteins play a role in modulating the function and localization of PKA, thereby influencing various cellular processes mediated by this kinase.
AKIPs can interact with different subunits of PKA. PKA is typically a tetrameric enzyme composed of two regulatory subunits and two catalytic subunits. In the presence of cAMP, PKA dissociates into its active catalytic subunits. AKIPs can bind to either the regulatory or the catalytic subunits, affecting the activation, localization, or substrate specificity of PKA.The interaction between AKIPs and PKA is significant for several cellular functions. PKA regulates various processes, including metabolism, gene expression, cell cycle progression, and apoptosis. By modulating PKA activity, AKIPs can indirectly influence these processes, impacting cellular homeostasis and response to external signals.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Activates adenylate cyclase, leading to increased cAMP levels and enhanced PKA activity, which can indirectly influence AKIP. | ||||||
H-89 dihydrochloride | 130964-39-5 | sc-3537 sc-3537A | 1 mg 10 mg | $94.00 $186.00 | 71 | |
A PKA inhibitor, H-89 can alter PKA signaling, potentially impacting AKIP function in a regulatory context. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
A non-selective inhibitor of phosphodiesterases, IBMX increases cAMP levels, indirectly affecting PKA and possibly AKIP. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
An inhibitor of phosphodiesterase 4 (PDE4), Rolipram increases cAMP levels, potentially influencing AKIP through enhanced PKA activity. | ||||||
8-Bromoadenosine 3′,5′-cyclic monophosphate | 23583-48-4 | sc-217493B sc-217493 sc-217493A sc-217493C sc-217493D | 25 mg 50 mg 100 mg 250 mg 500 mg | $108.00 $169.00 $295.00 $561.00 $835.00 | 2 | |
A cAMP analog that activates PKA, 8-Br-cAMP can indirectly influence AKIP function. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $92.00 $357.00 | 16 | |
A PDE3 inhibitor, Cilostamide increases cAMP levels, potentially affecting PKA and AKIP indirectly. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
Another cAMP analog that activates PKA, potentially influencing AKIP. | ||||||
Sp-cAMPS | 93602-66-5 | sc-201571 | 1 mg | $97.00 | 3 | |
A cAMP analog resistant to hydrolysis, Sp-cAMPS activates PKA, potentially influencing AKIP. | ||||||
PKI (14-22) amide (myristoylated) | 201422-03-9 | sc-471154 | 0.5 mg | $135.00 | 2 | |
A specific PKA inhibitor peptide, myristoylated PKI can alter PKA activity, potentially impacting AKIP function. | ||||||